Your browser is no longer supported. Please, upgrade your browser.
AERI Aerie Pharmaceuticals, Inc. daily Stock Chart
AERI [NASD]
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.19 Insider Own2.00% Shs Outstand42.67M Perf Week4.37%
Market Cap866.20M Forward P/E- EPS next Y-1.21 Insider Trans35.20% Shs Float39.82M Perf Month-10.02%
Income-232.00M PEG- EPS next Q-0.75 Inst Own- Short Float30.57% Perf Quarter13.73%
Sales48.50M P/S17.86 EPS this Y-35.90% Inst Trans1.89% Short Ratio13.72 Perf Half Y-15.31%
Book/sh4.60 P/B4.41 EPS next Y25.50% ROA-73.60% Target Price38.75 Perf Year-49.30%
Cash/sh7.99 P/C2.54 EPS next 5Y- ROE-118.20% 52W Range17.15 - 50.10 Perf YTD-16.01%
Dividend- P/FCF- EPS past 5Y2.60% ROI-92.10% 52W High-62.08% Beta0.51
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin96.60% 52W Low10.79% ATR1.21
Employees353 Current Ratio5.40 Sales Q/Q153.40% Oper. Margin- RSI (14)37.56 Volatility7.85% 5.14%
OptionableYes Debt/Eq0.88 EPS Q/Q44.40% Profit Margin- Rel Volume0.91 Prev Close20.30
ShortableYes LT Debt/Eq0.88 EarningsFeb 20 AMC Payout- Avg Volume887.04K Price19.00
Recom1.90 SMA20-7.07% SMA50-14.86% SMA200-22.08% Volume476,347 Change-6.40%
Jan-10-20Initiated BofA/Merrill Neutral $27
Jan-09-20Initiated SunTrust Buy $32
Dec-19-19Initiated Citigroup Buy $36
Nov-07-19Reiterated H.C. Wainwright Buy $55 → $41
Oct-30-19Reiterated Needham Buy $54 → $48
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Mar-09-17Downgrade Raymond James Strong Buy → Mkt Perform
Mar-08-17Reiterated RBC Capital Mkts Outperform $54 → $55
Mar-08-17Reiterated Needham Buy $52 → $58
Feb-17-17Initiated ROTH Capital Buy $69
Nov-01-16Initiated Aegis Capital Buy
Feb-24-20 02:59PM  Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus American City Business Journals -5.97%
07:30AM  Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-21-20 07:39PM  Edited Transcript of AERI earnings conference call or presentation 20-Feb-20 10:00pm GMT Thomson Reuters StreetEvents +8.55%
11:30AM  Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat Zacks
07:46AM  The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga
Feb-20-20 05:35PM  Aerie Pharmaceuticals (AERI) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update Business Wire
10:50AM  Some Market Stats In 5 Minutes Benzinga
Feb-18-20 06:30AM  Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax Business Wire
Feb-13-20 07:30AM  Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020 Business Wire
Feb-12-20 05:13AM  Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St.
Feb-03-20 06:30AM  Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs Business Wire
Jan-21-20 06:30AM  Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Business Wire
Jan-08-20 05:18PM  How Did Aerie Pharmaceuticals Inc (AERI) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Jan-07-20 05:26AM  Does Aerie Pharmaceuticals (NASDAQ:AERI) Have A Healthy Balance Sheet? Simply Wall St.
Jan-03-20 10:04AM  Aerie's (AERI) Application for Roclanda Accepted in Europe Zacks
Jan-02-20 08:46AM  The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe Benzinga
06:30AM  Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe Business Wire
Dec-09-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance Business Wire +5.91%
Dec-06-19 11:31AM  Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-19 09:19AM  Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy ? Insider Monkey +6.32%
Dec-03-19 06:15AM  Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe Business Wire
Dec-02-19 04:56AM  Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares? Simply Wall St.
Nov-27-19 09:45AM  5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace
Nov-26-19 06:30AM  Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
06:30AM  Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-22-19 08:18AM  The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 06:30AM  Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% Business Wire
Nov-19-19 10:58AM  Aerie buys Spanish outfit as it moves toward profitability American City Business Journals
09:31AM  Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex Zacks
Nov-18-19 06:30AM  Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program Business Wire
Nov-12-19 07:30AM  Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference Business Wire
05:41AM  Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 10:51AM  Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed Zacks -22.42%
07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
Nov-06-19 06:05PM  Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Nov-05-19 06:30AM  Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan Business Wire
Oct-30-19 07:30AM  Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019 Business Wire
06:30AM  Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer Business Wire
Oct-29-19 10:33AM  Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-28-19 06:13PM  Is Aerie Pharmaceuticals Inc (AERI) Going To Burn These Hedge Funds ? Insider Monkey +5.44%
Oct-25-19 06:40AM  Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62% Simply Wall St.
Oct-24-19 06:30AM  Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule Business Wire
Oct-16-19 07:15PM  Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-07-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer Business Wire
Sep-25-19 07:30AM  Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-23-19 01:20PM  Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks
Sep-20-19 06:30AM  Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union Business Wire
Sep-19-19 07:39AM  The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga +5.87%
06:37AM  Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money? Simply Wall St.
06:30AM  Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility Business Wire
Sep-16-19 11:46AM  Weekly CEO Buys Highlight GuruFocus.com +7.92%
Sep-10-19 09:36PM  Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aeries 1.50% Convertible Senior Notes Due 2024 Business Wire +8.26%
Sep-09-19 07:15PM  Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Bought $499,012 of Shares GuruFocus.com +8.77%
06:00AM  These 2 Biotech Stocks Are Seeing Insider Buying Activity TheStreet.com
Sep-06-19 02:42PM  Durham pharma embarks on $275M financial trade American City Business Journals
09:31AM  Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound? Zacks
Sep-05-19 08:12AM  The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga
Sep-04-19 08:20PM  Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024 Business Wire -9.31%
Sep-03-19 04:01PM  Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024 Business Wire -5.82%
Aug-26-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs Business Wire
Aug-20-19 06:30AM  Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Business Wire -5.78%
Aug-19-19 01:56PM  Zuckerberg Sells Shares of Facebook GuruFocus.com
Aug-08-19 04:08PM  This Biotech Crashed On 'Erroneous' Report Plus 2 Stocks That Diverged Investor's Business Daily +6.65%
09:25AM  Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance Zacks
09:02AM  Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St.
01:50AM  Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 06:05PM  Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Jul-31-19 10:36AM  Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-28-19 09:23PM  Analysts Recommend Buying These 2 Falling Knives GuruFocus.com
Jul-25-19 07:30AM  Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019 Business Wire
Jul-18-19 06:26PM  Allergan Announces FDA Acceptance of Glaucoma Candidate NDA Zacks
08:22AM  Hatteras Ventures-backed firm adds fresh round of capital American City Business Journals
Jul-11-19 06:46AM  How a Durham firm stands to benefit from an unexpected break in a Japanese trial American City Business Journals
Jul-09-19 05:48PM  Aerie Completes Enrollment Under Rhopressa Study in Japan Zacks
06:30AM  Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule Business Wire
Jun-24-19 08:50AM  Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza Zacks
Jun-20-19 07:09PM  Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy? Insider Monkey
Jun-17-19 09:47PM  Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
06:30AM  Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting Business Wire
Jun-11-19 07:30AM  Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
Jun-06-19 01:58PM  Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price? Simply Wall St. -6.09%
09:31AM  Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report? Zacks
May-28-19 07:30AM  Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-21-19 05:36PM  Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint Zacks
May-08-19 02:45PM  Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates Zacks +7.50%
May-07-19 10:46PM  Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript Motley Fool -5.37%
06:15PM  Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:09PM  Aerie: 1Q Earnings Snapshot Associated Press
04:01PM  Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-03-19 02:42PM  Another $100 million 'safety net' set for this Triangle pharma American City Business Journals
May-02-19 06:33PM  Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M Business Wire
12:42PM  Heres What Hedge Funds Think About Aerie Pharmaceuticals Inc (AERI) Insider Monkey
May-01-19 12:00PM  With profits in sight, Durham pharma launches new trials American City Business Journals
06:30AM  Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives Business Wire
Apr-30-19 07:30AM  Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019 Business Wire
Apr-25-19 06:30AM  Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant Business Wire
Apr-11-19 10:05AM  Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside TheStreet.com
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kopczynski Casey C.Chief Scientific OfficerDec 03Option Exercise0.41117,00047,385218,511Dec 05 04:06 PM
RUBINO RICHARD JChief Financial OfficerSep 09Buy19.935,040100,447339,446Sep 09 05:45 PM
ANIDO VICENTE JRChief Executive OfficerSep 09Buy19.0126,250498,953197,631Sep 09 05:43 PM
Foresite Capital Management II10% OwnerSep 05Buy18.4215,700289,1942,350,477Sep 06 08:28 PM
Foresite Capital Management II10% OwnerSep 04Buy18.48100,2001,851,6962,334,777Sep 06 08:28 PM
Foresite Capital Management II10% OwnerSep 03Buy20.8150,0001,040,7412,325,477Sep 04 08:38 PM
Foresite Capital Management II10% OwnerAug 30Buy21.3625,000534,0002,275,477Sep 04 08:38 PM
Foresite Capital Management II10% OwnerAug 23Buy23.4238,300896,9862,250,477Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 22Buy23.686,700158,6562,212,177Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 21Buy23.251,15326,8072,205,477Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 20Buy23.2150,0001,160,5002,204,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 19Buy23.343,84789,7892,154,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 16Buy24.23100,0002,423,0002,150,477Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 14Buy23.73100,0002,373,0002,050,477Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 13Buy25.35250,0006,337,3421,310,000Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 12Buy24.43189,5554,630,8291,060,000Aug 14 08:15 PM